A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment Compared With Adult Participants With Normal Hepatic Function
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Emraclidine (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Pharmacokinetics
- Sponsors AbbVie; Cerevel Therapeutics
Most Recent Events
- 05 Mar 2025 Status changed from recruiting to completed.
- 20 Feb 2025 Planned End Date changed from 23 Dec 2024 to 1 Feb 2025.
- 20 Feb 2025 Planned primary completion date changed from 15 Dec 2024 to 1 Feb 2025.